Sep 2026
A novel cyclic-peptide antagonist of TIM-3 for cancer immunotherapy by reinvigorating exhausted T-cell activity.
TBP1 is identified as a novel TIM-3-targeting cyclic peptide, which binds TIM-3 with high affinity and specificity, and support its potential application in combination immune checkpoint blockade.
Ying Huang, Jia-Le Li, Yin-Hui Qin et al.
· European Journal of Pharmaco... · 0 citations